TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: USDA Healthy Incentives Pilot (HIP)
Brief Summary: The USDA Healthy Incentives Pilot (HIP) evaluated the impact of a 30% financial incentive on fruit and vegetable intake among adult participants in the USDA Supplemental Nutrition and Assistance Program (SNAP).


Options:
A: Arm Label: HIP; Type: EXPERIMENTAL; Interventions: Other: HIP | Arm Label: Non-HIP; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: HIP; Assigned to Arm(s): HIP
B: Arm Label: Homestead Food Production; Type: EXPERIMENTAL; Interventions: Behavioral: Homestead Food Production program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Homestead Food Production program; Assigned to Arm(s): Homestead Food Production
C: Arm Label: Unconditional cash transfers; Type: EXPERIMENTAL; Interventions: Behavioral: Zomba Cash Transfer Program | Arm Label: Conditional Cash Transfer; Type: EXPERIMENTAL; Interventions: Behavioral: Zomba Cash Transfer Program | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Zomba Cash Transfer Program; Assigned to Arm(s): Conditional Cash Transfer, Unconditional cash transfers
D: Arm Label: Homestead Food Production plus small pond aquaculture; Type: EXPERIMENTAL; Interventions: Behavioral: Homestead Food Production plus small pond aquaculture | Arm Label: plant-based Homestead Food Production; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: plant-based Homestead Food Production | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Behavioral: a comparison group | Intervention Type: BEHAVIORAL; Name: plant-based Homestead Food Production; Assigned to Arm(s): plant-based Homestead Food Production | Intervention Type: BEHAVIORAL; Name: Homestead Food Production plus small pond aquaculture; Assigned to Arm(s): Homestead Food Production plus small pond aquaculture | Intervention Type: BEHAVIORAL; Name: a comparison group; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: USDA Healthy Incentives Pilot (HIP)
Brief Summary: The USDA Healthy Incentives Pilot (HIP) evaluated the impact of a 30% financial incentive on fruit and vegetable intake among adult participants in the USDA Supplemental Nutrition and Assistance Program (SNAP).


Options:
A: Arm Label: HIP; Type: EXPERIMENTAL; Interventions: Other: HIP | Arm Label: Non-HIP; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: HIP; Assigned to Arm(s): HIP
B: Arm Label: Outpatient therapeutic program, counseling and cash transfer; Type: EXPERIMENTAL; Interventions: Other: Outpatient therapeutic program, counseling and cash transfer | Arm Label: Outpatient therapeutic program and counseling; Type: ACTIVE_COMPARATOR; Interventions: Other: Outpatient therapeutic program and counseling | Intervention Type: OTHER; Name: Outpatient therapeutic program, counseling and cash transfer; Assigned to Arm(s): Outpatient therapeutic program, counseling and cash transfer | Intervention Type: OTHER; Name: Outpatient therapeutic program and counseling; Assigned to Arm(s): Outpatient therapeutic program and counseling
C: Arm Label: Program participation; Type: EXPERIMENTAL; Interventions: Other: Enhanced-Homestead Food Production Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Enhanced-Homestead Food Production Program; Assigned to Arm(s): Program participation
D: Arm Label: Homestead Food Production plus small pond aquaculture; Type: EXPERIMENTAL; Interventions: Behavioral: Homestead Food Production plus small pond aquaculture | Arm Label: plant-based Homestead Food Production; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: plant-based Homestead Food Production | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Behavioral: a comparison group | Intervention Type: BEHAVIORAL; Name: plant-based Homestead Food Production; Assigned to Arm(s): plant-based Homestead Food Production | Intervention Type: BEHAVIORAL; Name: Homestead Food Production plus small pond aquaculture; Assigned to Arm(s): Homestead Food Production plus small pond aquaculture | Intervention Type: BEHAVIORAL; Name: a comparison group; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: USDA Healthy Incentives Pilot (HIP)
Brief Summary: The USDA Healthy Incentives Pilot (HIP) evaluated the impact of a 30% financial incentive on fruit and vegetable intake among adult participants in the USDA Supplemental Nutrition and Assistance Program (SNAP).


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Rewards; Type: EXPERIMENTAL; Interventions: Behavioral: F&V Bonus | Arm Label: Restrictions; Type: EXPERIMENTAL; Interventions: Behavioral: Restriction | Arm Label: Rewards plus restrictions; Type: EXPERIMENTAL; Interventions: Behavioral: Bonus & Restriction | Intervention Type: BEHAVIORAL; Name: F&V Bonus; Assigned to Arm(s): Rewards | Intervention Type: BEHAVIORAL; Name: Restriction; Assigned to Arm(s): Restrictions | Intervention Type: BEHAVIORAL; Name: Bonus & Restriction; Assigned to Arm(s): Rewards plus restrictions
B: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Policy and Environmental Change; Type: EXPERIMENTAL; Interventions: Behavioral: Policy and Environmental Change | Intervention Type: BEHAVIORAL; Name: Policy and Environmental Change; Assigned to Arm(s): Policy and Environmental Change
C: Arm Label: HIP; Type: EXPERIMENTAL; Interventions: Other: HIP | Arm Label: Non-HIP; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: HIP; Assigned to Arm(s): HIP
D: Intervention Type: BEHAVIORAL; Name: Promotion of a healthy diet and physical activity; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Avoidance of Alcohol, Drugs, and Tobacco; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-Arm, Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)
Brief Summary: The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen in adults with chronic HCV genotype 1 - 6 infection and chronic severe renal impairment.


Options:
A: Arm Label: Peginterferon alfa-2a and ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Peginterferon alfa-2a and ribavirin | Arm Label: Peginterferon alfa-2a; Type: EXPERIMENTAL; Interventions: Drug: Peginterferon alfa-2a | Intervention Type: DRUG; Name: Peginterferon alfa-2a and ribavirin; Assigned to Arm(s): Peginterferon alfa-2a and ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2a; Assigned to Arm(s): Peginterferon alfa-2a
B: Arm Label: Immediate Treatment; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: Deferred Treatment; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Placebo to Grazoprevir, Drug: Placebo to Elbasvir | Arm Label: Intensive PK; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Intervention Type: DRUG; Name: Grazoprevir; Assigned to Arm(s): Deferred Treatment, Immediate Treatment, Intensive PK | Intervention Type: DRUG; Name: Elbasvir; Assigned to Arm(s): Deferred Treatment, Immediate Treatment, Intensive PK | Intervention Type: DRUG; Name: Placebo to Grazoprevir; Assigned to Arm(s): Deferred Treatment | Intervention Type: DRUG; Name: Placebo to Elbasvir; Assigned to Arm(s): Deferred Treatment
C: Arm Label: hepatitis C and/or B; Type: N/A; Interventions: N/A
D: Arm Label: ABT-493/ABT-530; Type: EXPERIMENTAL; Interventions: Drug: ABT-493/ABT-530 | Intervention Type: DRUG; Name: ABT-493/ABT-530; Assigned to Arm(s): ABT-493/ABT-530

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MOBILE Trial. Mechanical and Oral Antibiotic Bowel Preparation Versus no Bowel preparatIon for eLEctive Colectomy - a Multicenter, Prospective, Randomized, Controlled Trial.
Brief Summary: Enchanced recovery after surgery (ERAS) protocols aim to provide safer and quicker recovery postoperatively. One of the elements in ERAS protocols is that bowel is not prepared before colorectal surgery. However, several recent retrospective register studies have suggested that mechanical bowel preparation combined to oral antibiotics before colectomy reduces complications compared to no preparation at all. This trial compares these two strategies to find out whether complications can indeed be reduced by mechanically preparing the bowel with oral antibiotics.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard operating management | Intervention Type: PROCEDURE; Name: standard operating management; Assigned to Arm(s): 2
B: Arm Label: Oral + Parenteral prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: Oral antibiotic drugs, Drug: Parenteral prophylaxis | Arm Label: Only parenteral prophylaxis; Type: SHAM_COMPARATOR; Interventions: Drug: Parenteral prophylaxis | Intervention Type: DRUG; Name: Oral antibiotic drugs; Assigned to Arm(s): Oral + Parenteral prophylaxis | Intervention Type: DRUG; Name: Parenteral prophylaxis; Assigned to Arm(s): Only parenteral prophylaxis, Oral + Parenteral prophylaxis
C: Arm Label: Mechanical and oral antibiotic bowel preparation; Type: EXPERIMENTAL; Interventions: Drug: neomycin, metronidazole, polyethylene glycol (PEG) | Arm Label: No bowel preparation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: neomycin, metronidazole, polyethylene glycol (PEG); Assigned to Arm(s): Mechanical and oral antibiotic bowel preparation
D: Arm Label: Standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Selective decontamination of the digestive tract (SDD); Type: EXPERIMENTAL; Interventions: Drug: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B) | Intervention Type: DRUG; Name: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B); Assigned to Arm(s): Selective decontamination of the digestive tract (SDD)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Open-Label, Active-Controlled Study of Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease on Dialysis
Brief Summary: This is a randomized, multicenter, open-label, active-controlled study of the treatment of anemia in subjects with CKD on dialysis, with treatment up to 52 weeks.


Options:
A: Arm Label: AKB-6548; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AKB-6548; Assigned to Arm(s): AKB-6548 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Molidustat, 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo | Arm Label: Molidustat, 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo | Arm Label: Molidustat, 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo | Arm Label: Molidustat, 160 mg; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat, 120 mg, Molidustat, 160 mg, Molidustat, 40 mg, Molidustat, 80 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Molidustat, 120 mg, Molidustat, 160 mg, Molidustat, 40 mg, Molidustat, 80 mg
C: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934)
D: Arm Label: FG-4592; Type: EXPERIMENTAL; Interventions: Drug: FG-4592 | Arm Label: EPO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: FG-4592; Assigned to Arm(s): FG-4592 | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): EPO

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis
Brief Summary: This is a randomized, multicenter, double-blind, placebo-controlled study of the treatment of anemia in subjects with CKD not on dialysis, with treatment up to 52 weeks.


Options:
A: Arm Label: FG-4592; Type: EXPERIMENTAL; Interventions: Drug: FG-4592 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FG-4592; Assigned to Arm(s): FG-4592 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Cohort A: Roxadustat Tiered, Weight Based Dosing TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Cohort B: Roxadustat Tiered, Weight Based Dosing TIW then BIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Cohort C: Roxadustat at 50 mg TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Cohort D: Roxadustat at 100 mg TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Cohort E: Roxadustat Tiered, Weight Based Dosing BIW then QW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Cohort F: Roxadustat at 70 mg BIW then QW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Cohort A: Roxadustat Tiered, Weight Based Dosing TIW, Cohort B: Roxadustat Tiered, Weight Based Dosing TIW then BIW, Cohort C: Roxadustat at 50 mg TIW, Cohort D: Roxadustat at 100 mg TIW, Cohort E: Roxadustat Tiered, Weight Based Dosing BIW then QW, Cohort F: Roxadustat at 70 mg BIW then QW
C: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
D: Arm Label: Daprodustat treated anemic subjects; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: Iron therapy | Arm Label: Darbepoetin alfa treated anemic subjects; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: Iron therapy | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Daprodustat treated anemic subjects | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa treated anemic subjects | Intervention Type: DRUG; Name: Iron therapy; Assigned to Arm(s): Daprodustat treated anemic subjects, Darbepoetin alfa treated anemic subjects

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Promoting Community Initiated Kangaroo Mother Care (KMC) for Low Birth Weight Infants
Brief Summary: This study is being conducted to assess the impact of promoting community initiated Kangaroo Mother Care (ciKMC) for low birth weight babies on post enrolment neonatal mortality and mortality post enrolment upto 6 months of age. This large individually randomized controlled trial will enroll 10500 low birth weight babies. The secondary objectives are examining the impact of the intervention on exclusive breast feeding and growth at 1 and 3 months, infections and hospitalizations in the neonatal period and from 1 to 5 months of age, recognition of illnesses and early care seeking from appropriate sources, motor and mental development in a subsample.

Newborns weighing \>=1500 to \<=2250gm are being enrolled into the study within 3 days of birth. Eligible babies are randomized to intervention or control arms. Mothers in the intervention arm are supported for KMC and breastfeeding by study ANM (Auxiliary Nurse Midwife) and study ASHA (Accredited Social Health Activist) like workers . Routine home visits are conducted in both intervention and control arms by government workers according to the existing government program.

Survival will be ascertained in all enrolled infants through contacts at 1, 3 and 6 months.

The data safety and monitoring committee (DSMC) conducted two interim analyses, first in September 2017 when about half of the infants had been enrolled, and second in June 2018, when almost three quarters of the enrolled babies had been followed till 28 days of age. Following the second interim analysis, the DSMC concluded that a sufficient number of infants would be enrolled by the end to September 2018 to clearly answer the study question concerning the impact of ciKMC on both neonatal and early infant mortality. The DSMC recommended that data collection be completed by the end of October 2018.


Options:
A: Intervention Type: DRUG; Name: Co-Trimoxazole; TMP-SMZ; Assigned to Arm(s): N/A
B: Arm Label: Home-based counselling visits by volunteers; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based counselling | Arm Label: Standard care through existing health system; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home-based counselling; Assigned to Arm(s): Home-based counselling visits by volunteers
C: Arm Label: Intervention Kangaroo Mother Care; Type: EXPERIMENTAL; Interventions: Behavioral: Kangaroo Mother Care | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Kangaroo Mother Care; Assigned to Arm(s): Intervention Kangaroo Mother Care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: IMNCI | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IMNCI; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MabThera Drug Utilisation Study and Patient Alert Card Evaluation in Non-Oncology Patients in Europe: An Infusion Centre-Based Approach
Brief Summary: This study is to characterize the indications for which rituximab is being used and to evaluate the use of the Patient Alert Card (PAC) in participants receiving the medication for non-oncology conditions at infusion centers. The study involves the retrospective chart review of rituximab users' medical records in non-oncology indications as well as a survey to collect information on participant characteristics, and will include questions about participant knowledge on the risk of infections, participant receipt and review of the PAC, and any actions the participant has taken as a result of receiving the PAC.


Options:
A: Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): N/A
B: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Arm Label: Baseline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): Placebo
C: Arm Label: Cohort; Type: N/A; Interventions: Biological: Rituximab | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Cohort
D: Arm Label: (Placebo and) Glatiramer Acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate, Other: Placebo | Arm Label: Rituximab and Glatiramer Acetate (R-GA); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Glatiramer Acetate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab and Glatiramer Acetate (R-GA) | Intervention Type: DRUG; Name: Glatiramer Acetate; Assigned to Arm(s): (Placebo and) Glatiramer Acetate, Rituximab and Glatiramer Acetate (R-GA) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): (Placebo and) Glatiramer Acetate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TIME - Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropscyhiatric Symptoms
Brief Summary: Almost all people who suffer from dementia experience neuropsychiatric symptoms (NPS) in the course of the disease. TIME (Targeted Interdisciplinary Model for Evaluation and treatment of neuropsychiatric symptoms) is a multicomponent intervention based on the theoretical framework of cognitive behavioral therapy (CBT). The TIME trial is designed to assess the effects of TIME on NPS in nursing homes patients with dementia and the implementation process at staff and organization level.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedical support; Type: ACTIVE_COMPARATOR; Interventions: Other: Telemedical support | Intervention Type: OTHER; Name: Telemedical support; Assigned to Arm(s): Telemedical support
B: Arm Label: TAPER; Type: EXPERIMENTAL; Interventions: Other: Medication reduction | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Medication reduction; Assigned to Arm(s): TAPER
C: Arm Label: normal care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: telemedicine | Intervention Type: PROCEDURE; Name: telemedicine; Assigned to Arm(s): telemedicine
D: Arm Label: INH (Intervention Nursing Homes); Type: EXPERIMENTAL; Interventions: Other: TIME | Arm Label: CNH (Control Nursing Homes); Type: ACTIVE_COMPARATOR; Interventions: Other: Education-only intervention | Intervention Type: OTHER; Name: TIME; Assigned to Arm(s): INH (Intervention Nursing Homes) | Intervention Type: OTHER; Name: Education-only intervention; Assigned to Arm(s): CNH (Control Nursing Homes)

Answer: D